Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib.
Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib.
Blood Res. 2019 Mar;54(1):77-79
Authors: Yi JH, Kim HR
PMID: 30956968 [PubMed]
Source: Blood Research - Category: Hematology Tags: Blood Res Source Type: research